SCHEMBL7356376

SCHEMBL7356376

CCCCC(=O)NC(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MAPT P10636 4/20 0.53
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MEN1 O00255 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PKM P14618 1/20 0.53
HSP90AA1 P07900 1/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
FAAH O00519 2/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.45
AKR1B1 P15121 1/20 0.44
TP53 P04637 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285375 0.93 HSP90AA1 (0.58) ALDH1A1MAPTKMT2AMEN1HSP90AA1
SCHEMBL29182622 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL3190449 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL28459110 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL12700294 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL25330155 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL29539510 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL6274637 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL14405350 0.91 HSP90AA1 (0.61) ALDH1A1KMT2AMEN1HSP90AA1CES2
SCHEMBL5147801 0.87 ALDH1A1 (0.59) ALDH1A1MAPTKDM4EKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005448-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS Du Pont Pharmaceuticals Company (US) 2000-06-07 EP claimed
WO-1999009000-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS DU PONT PHARMACEUTICALS COMPANY (US) 1999-02-25 WO claimed
CN-114432301-B Covalent inhibitor derivative and application thereof in treatment of viral infection 北京大学 2024-05-31 CN disclosed
CN-115814713-A System and method for preparing adiponitrile from adipic acid 中国石油化工股份有限公司 2023-03-21 CN disclosed
EP-4077289-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2022-10-26 EP disclosed
CN-104245814-B Rubber composition 湛新德国有限公司 2016-11-09 CN disclosed
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 US disclosed
CN-104245814-A Rubber compositions CYTEC SURFACE SPECIALTIES GERMANY GMBH 2014-12-24 CN disclosed
CN-103282448-A Non-aqueous dispersions comprising a nonlinear acrylic stabilizer PPG IND OHIO INC 2013-09-04 CN disclosed
CN-1168702-C Movel acyl pseudodipeoptides, prepn method and pharmaceutical compsns. contg. same OMҩҵ 2004-09-29 CN disclosed
CN-1385469-A Asphalt liquefying agent CHENGDU ORGANIC CHEM INST (CN) 2002-12-18 CN disclosed
CN-1306504-A Movel acyl pseudodipeoptides, prepn method and pharmaceutical compsns. contg. same OM PHARMA (CH) 2001-08-01 CN disclosed
EP-1005448-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS Du Pont Pharmaceuticals Company (US) 2000-06-07 EP disclosed
WO-1999009000-A2 NOVEL INHIBITORS OF AGGRECANASE AND MATRIX METALLOPROTEINASES FOR THE TREATMENT OF ARTHRITIS DU PONT PHARMACEUTICALS COMPANY (US) 1999-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051185-A1 Chemical Compounds 251 PIM1, PIM3, PIM2 ALDH1A1 683/4885MAPT 3277/4885KDM4E 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.